Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Apellis Pharmaceuticals

Request full access

Platform of novel therapeutic compounds for the treatment of autoimmune diseases

Waltham, United StatesFounded 2008Biotech & Life Sciences

About Apellis Pharmaceuticals

Apellis Pharmaceuticals was founded in 2009 by Cedric Francois and Pascal Deschatelets, two visionaries with a deep commitment to advancing medical science. Their mission was to develop innovative therapies targeting the complement system, a part of the immune system that plays a crucial role in inflammation and disease.

The company quickly gained attention for its pioneering work in complement inhibition, focusing on diseases with significant unmet medical needs. Apellis's approach was to develop therapies that could precisely target and modulate the complement cascade, offering new hope for patients with rare and debilitating conditions.

A significant milestone in Apellis's journey was its Initial Public Offering (IPO) in November 2017. This event marked a new chapter for the company, providing the financial resources needed to accelerate its research and development efforts. The IPO was a testament to the confidence investors had in Apellis's innovative approach and potential for growth.

In 2025, Apellis made headlines again with a strategic partnership with Sobi, a Swedish biopharmaceutical company. This deal, valued at up to $300 million, involved the sale of ex-US royalties for Apellis's drug Aspaveli. The partnership not only provided Apellis with substantial capital but also expanded its reach in the global market.

Today, Apellis Pharmaceuticals continues to push the boundaries of medical science, driven by a commitment to improve the lives of patients worldwide. Its journey from a small startup to a leader in complement therapies is a testament to the power of innovation and strategic partnerships in the biopharmaceutical industry.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2017

Apellis Pharmaceuticals in the Waltham ecosystem

Live from Dealroom

The Apellis Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

18 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Series B and later16 investors entered at this stage

Team profiled 23 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$51M

29 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Apellis Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.